Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: The first case-control blinded study

被引:0
作者
Khorvash, Fariborz [1 ]
Farajpour-Khanaposhtani, Mohammad Javad [2 ]
Hemasian, Helia [2 ]
Saadatnia, Sayed Mohammad [1 ]
机构
[1] Isfahan Univ Med Sci, Isfahan Neurosci Res Ctr, Esfahan, Iran
[2] Isfahan Univ Med Sci, Sch Med, Dept Neurol, Esfahan, Iran
来源
CURRENT JOURNAL OF NEUROLOGY | 2021年 / 20卷 / 03期
关键词
Cerebral Veins; Thrombosis; Warfarin; Rivaroxaban; VENOUS SINUS THROMBOSIS; RISK;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Anticoagulation therapy following cerebral vein thrombosis (CVT) can improve mortality and morbidity. Vitamin K antagonists are currently the routine oral anticoagulant used for CVT; while by introduction of rivaroxaban, a direct factor Xa inhibitor, the attentions have been deviated toward novel agents, but the evidence is not strong. The current study is aimed to compare the efficacy and safety of rivaroxaban versus warfarin for anticoagulation therapy of CVT. Methods: The current randomized clinical trial has been conducted on 50 patients with CVT among which, 25 ones were randomly allocated to rivaroxaban treatment (20 mg per day for three months) and remained 25 ones to warfarin treatment [adjusted based on international normalized ratio (INR) of 2-3]. The Modified Rankin Scale (mRS) and clinical investigations, including the incidence of seizure, papilledema, intra/extra-cranial bleeding, blurred vision, headache, nausea and vomiting, and death were evaluated at discharge time and within 3 and 6 months following CVT incidence; eventually, two groups were compared. Results: Comparison of mRS scores between the groups revealed significant differences in none of the interval assessments, at the time of admission (P = 0.51), within three months (P = 0.63), and within six months (P = 0.99), while both of the approaches led to significant decrease in mRS scoresfollowing both of the treatments (P < 0.001). The comparison of drug-related adverse effects showed insignificant difference between warfarin versus rivaroxaban (P > 0.05). Conclusion: Based on this study, rivaroxaban is an efficacious agent for the treatment of CVT without remarkable adverse effects.
引用
收藏
页数:6
相关论文
共 21 条
[1]  
Anticoli S., 2016, J BIOMEDICAL SCI, V5, P1, DOI DOI 10.4172/2254-609X.100031
[2]   Outcomes validity and reliability of the modified Rankin scale: Implications for stroke clinical trials - A literature review and synthesis [J].
Banks, Jamie L. ;
Marotta, Charles A. .
STROKE, 2007, 38 (03) :1091-1096
[3]   Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].
Bauersachs, Rupert ;
Berkowitz, Scott D. ;
Brenner, Benjamin ;
Buller, Harry R. ;
Decousus, Herve ;
Gallus, Alex S. ;
Lensing, Anthonie W. ;
Misselwitz, Frank ;
Prins, Martin H. ;
Raskob, Gary E. ;
Segers, Annelise ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Bounameaux, Henri ;
Cohen, Alexander ;
Davidson, Bruce L. ;
Piovella, Franco ;
Schellong, Sebastian .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510
[4]   Apixaban and rivaroxaban in patients with cerebral venous thrombosis [J].
Covut, Fahrettin ;
Kewan, Tariq ;
Perez, Oscar ;
Flores, Monica ;
Haddad, Abdo ;
Daw, Hamed .
THROMBOSIS RESEARCH, 2019, 173 :77-78
[5]   Death and disability from warfarin-associated intracranial and extracranial hemorrhages [J].
Fang, Margaret C. ;
Go, Alan S. ;
Chang, Yuchiao ;
Hylek, Elaine M. ;
Henault, Lori E. ;
Jensvold, Nancy G. ;
Singer, Daniel E. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (08) :700-705
[6]   Prognosis of cerebral vein and dural sinus thrombosis - Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) [J].
Ferro, JM ;
Canhao, P ;
Stam, J ;
Bousser, MG ;
Barinagarrementeria, F .
STROKE, 2004, 35 (03) :664-670
[7]   Novel Factor Xa Inhibitor for the Treatment of Cerebral Venous and Sinus Thrombosis First Experience in 7 Patients [J].
Geisbuesch, Christina ;
Richter, Daniel ;
Herweh, Christian ;
Ringleb, Peter A. ;
Nagel, Simon .
STROKE, 2014, 45 (08) :2469-2471
[8]   Cerebral vein and dural sinus thrombosis in adults in Isfahan, Iran: frequency and seasonal variation [J].
Janghorbani, M. ;
Zare, M. ;
Saadatnia, M. ;
Mousavi, S. A. ;
Mojarrad, M. ;
Asgari, E. .
ACTA NEUROLOGICA SCANDINAVICA, 2008, 117 (02) :117-121
[9]   Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis [J].
Linkins, LA ;
Choi, PT ;
Douketis, JD .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (11) :893-900
[10]   Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review [J].
Luo, Yaxi ;
Tian, Xin ;
Wang, Xuefeng .
FRONTIERS IN AGING NEUROSCIENCE, 2018, 10